Gene Disease Score gda Association Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 673
Gene Symbol: BRAF
BRAF
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis
0.400 AlteredExpression BEFREE In melanoma, constitutive activation of the BRAF/MEK/ERK (MAPK) and PI3K/AKT/mTOR (PI3K) signaling pathways plays a pivotal role in cell proliferation, survival and tumorigenesis. 26299806

2015

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis
0.400 AlteredExpression BEFREE Several lines of evidence indicate that mutational activation of KRAS is an early event in the carcinogenesis of non-small cell lung cancer (NSCLC). 23022742

2013

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis
0.400 AlteredExpression BEFREE The amplification and overexpression of the erbB-2 oncogene and its involvement in tumorigenesis makes this receptor an appropriate target for specific agents directed towards tumor cells. 10515198

1999

Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis
0.400 AlteredExpression BEFREE These results indicate that RD deletion and BMI1 overexpression frequently occur in the early stage of oral carcinogenesis and BMI1 overexpression may downregulate the transcription of p16 and p14 through interfering with RD. 24302590

2015

Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis
0.400 AlteredExpression BEFREE Our observation of frequent p14 gene abnormalities (90%) and inactivation (40-60%) was in striking contrast to the same pathological subtype of systemic lymphoma in which p14 gene abnormalities and inactivation were infrequent, suggesting a difference in carcinogenesis between PCNSL and systemic lymphoma. 15649253

2005

Entrez Id: 4780
Gene Symbol: NFE2L2
NFE2L2
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis
0.400 AlteredExpression BEFREE We have previously shown that KSHV utilizes the host transcription factor Nrf2 to aid in infection of endothelial cells and oncogenesis. 25995248

2015

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis
0.400 AlteredExpression BEFREE On the basis of this background, we tested whether Curaxin-137 could suppress tumorigenesis in MMTV-neu transgenic mice, which spontaneously develop mammary carcinoma due to steroid receptor-regulated expression of the Her2 proto-oncogene. 22689915

2012

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis
0.400 AlteredExpression BEFREE It has been implicated in mammary carcinogenesis through its regulation of HER-2/neu proto-oncogene and estrogen receptor gene The hAP-2gamma gene is located on human chromosome 20q13.2. 12490322

2002

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis
0.400 AlteredExpression BEFREE Our findings suggest that mutational activation of the K-ras gene is a common event in colon carcinogenesis and that HPV infection may represent an important factor in the development of the premalignant lesions leading to the neoplastic phenotype. 16672071

2006

Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis
0.400 AlteredExpression BEFREE Expression of two viral oncogenes, E6 and E7, in epithelial stem cells is required to initiate and maintain cervical carcinogenesis and results in significant overexpression of the cellular p16INK4a protein. 11790875

2001

Entrez Id: 857
Gene Symbol: CAV1
CAV1
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis
0.400 AlteredExpression BEFREE Although none of these four genes showed significant expression differences between PCa ERG+ and PCa ETS-, CAV1, IGFBP3 and TGFBR2 were less expressed in PCa in an independent series of 56 PCa and 15 NPT, as also observed for ECRG4 and LDOC1, suggesting a role in prostate carcinogenesis in general. 23185447

2012

Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis
0.400 AlteredExpression BEFREE No association was established between occurrence of genetic aberrations at 9p21 and tumor stage or grade, supporting previous suggestions that CDKN2A/ARF inactivation is an early event in bladder carcinogenesis. 12538475

2003

Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis
0.400 AlteredExpression BEFREE HPV-16 integration could be directly related to tonsillar carcinogenesis initially in tonsillar crypts, followed by cell cycle aberration such as p16 overexpression related to the G1-S phase. 17205528

2007

Entrez Id: 857
Gene Symbol: CAV1
CAV1
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis
0.400 AlteredExpression BEFREE Lack of caveolin-1 expression has been implicated in the pathogenesis of oncogenic cell transformation and tumorigenesis in many cancers. 16865235

2006

Entrez Id: 857
Gene Symbol: CAV1
CAV1
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis
0.400 AlteredExpression BEFREE High expression of Cav-1 in nasopharyngeal carcinoma (NPC) may enhance tumor cell migration and correlate with poor prognosis of the patients, while the genetic alterations of Cav-1 during nasopharyngeal carcinogenesis are still largely unknown. 21965789

2011

Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis
0.400 AlteredExpression BEFREE The expression loss of p16 protein related to the gastric carcinogenesis, gastric carcinoma histopathological subtypes and lymph metastasis. 11819820

2001

Entrez Id: 406986
Gene Symbol: MIR203A
MIR203A
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis
0.400 AlteredExpression BEFREE In summary, our study determined that miR-203a down-regulation is closely related to tumorigenesis in bladder cancer; thus suggesting that miR-203a is a potential prognostic marker and a potential target in bladder cancer treatment. 30509104

2019

Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis
0.400 AlteredExpression BEFREE These results suggested that the MTS1/CDK4I gene is a tumor suppressor the inactivation of which plays an important role during carcinogenesis of the squamous cell type of esophageal carcinoma. 8012957

1994

Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis
0.400 AlteredExpression BEFREE Inactivation of p16 has been reported as one of the more frequent events in human carcinogenesis. 14719111

2004

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis
0.400 AlteredExpression BEFREE Finally, we show that IRS4 and ERBB2/HER2 synergistically induce tumorigenesis and that IRS4-expression confers resistance to HER2-targeted therapy. 27876799

2016

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis
0.400 AlteredExpression BEFREE Overexpression of erbB-2 plays a key role in tumorigenesis or progression such as breast cancer and ovarian cancer. 19242112

2009

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis
0.400 AlteredExpression BEFREE Thus, the activated Ki-ras gene plays a key role in colorectal tumorigenesis through altered cell differentiation and cell growth. 8465203

1993

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis
0.400 AlteredExpression BEFREE Differences between phosphotyrosine accumulation and Neu/ErbB-2 receptor expression in astrocytic proliferative processes. Implications for glial oncogenesis. 8826951

1996

Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis
0.400 AlteredExpression BEFREE FOXA1 antagonizes EZH2-mediated CDKN2A repression in carcinogenesis. 25264199

2014

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis
0.400 AlteredExpression BEFREE Collectively, the present findings suggest that EVI1 overexpression and KRAS mutation converge on activation of the KRAS pathway in early phases of pancreatic carcinogenesis and propose EVI1 and/or miR-96 as early markers and therapeutic targets in this dismal disease. 23752186

2014